For instance, MEF2C was identified as a candidate gene/molecular marker for the transition from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) and evaluated by RT-PCR. Here, MEF2C is linked to ductal breast carcinoma in situ.